

ORAL PRESENTATION

Open Access

Short-term evaluation of immediately-treated patients with acute HIV infection, recently diagnosed in the National Institute for Infectious Diseases “Prof. Dr. Matei Balș”, Bucharest, Romania

Ruxandra Moroti^{1,2*}, Adriana Hristea^{1,2}, Violeta Molagic², Raluca Jipa^{2,3}, Mihaela Iosipenco², Doina Rîciu², Dan Oțelea², Dragoș Florea^{1,2}, Valeriu Gheorghiuță^{2,3}, Raluca Hrișcă^{2,3}, Ioan Diaconu², Adrian Streinu-Cercel^{1,2}, Otilia Benea^{1,2}

From The 10th Edition of the Scientific Days of the National Institute for Infectious Diseases “Prof Dr Matei Bals”

Bucharest, Romania. 15-17 October 2014

Background

The rapidly put-on-treatment in acute HIV infection (AHI) seems to achieve functional cure in up to 15% cases. This represents a huge difference, spontaneous elite-controllers being less than 0.5%.

Objective: To identify the AHI patients and to observe the immune-virological course under immediately-started antiretroviral treatment (ART).

Methods

All newly-diagnosed HIV-infected adults (>18 yo) in the last 18 months (01.2013-06.2014) in an infectious diseases hospital were considered. The including criteria for AHI group were: detectable HIV-RNA or positive antigen/antibody combination assays in the setting of a negative/indeterminate HIV Western blot. AHI group was classified accordingly to Fiebig stages and was further evaluated regarding CD4 count and viral load (VL) at diagnosis, at 3 and 6 months. ART initiation and the regimen were also registered.

Results

804 adults were newly-diagnosed HIV-positive, out of which 26 patients (2.32%) with AHI. The number of

patients in Fiebig II/III, IV, V and VI stages was 8, 15, 2 and 1 respectively. The AHI-group had a median age of 31, IQR [25-34] and 3.1:1 male:female ratio. The median CD4 count was 435, IQR [251-775] and the median VL was 5.6 log₁₀, IQR [4.7-7]. Eight out of 26 AHI patients immediately started ART, in Fiebig II/III and IV stages for 7 of them. The 8th received ARV treatment in eclipse phase (for 28 days, as post-exposure prophylaxis) then restarted ART in Fiebig VI stage, at diagnosis moment. The immediately-treated group had a median age of 24, IQR [20-29], a male:female ratio of 7:1 and all were symptomatic. The median CD4 count at diagnosis was 261, IQR [147-467] and the median VL was 7 log₁₀, IQR [5.6-7], except the partially-treated in eclipse-phase patient, whose CD4 count was 789 and VL was 21977c/mL at diagnosis. In the immediately-treated group there was a rise in median CD4 count to 646, IQR [544-764] at month 3 and to 755, IQR [577-950] at month 6. The median VL declines to 1.6 log₁₀, IQR [1.3-2.2] at month 6. Five patients received a 3-drugs regimen and 3 received a 4-drugs regimen. The immune-virological course couldn't be correlated with a particular regimen or with the number of drugs used.

Conclusion

Two percent of newly diagnosed HIV-infected patient in 18 months in our setting had AHI and one third of

* Correspondence: ruxandra_moroti@yahoo.com

¹Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Full list of author information is available at the end of the article

them received immediate treatment. The short-term benefit was the consistent immune-virological improvement, regardless of ART scheme. However, more than half had detectable VL at month 6, probable due to the very high initial VL.

Authors' details

¹Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

²National Institute for Infectious Diseases "Prof. Dr. Matei Balș", Bucharest, Romania. ³Central University Emergency Military Hospital Dr Carol Davila, Bucharest, Romania.

Published: 15 October 2014

doi:10.1186/1471-2334-14-S7-O1

Cite this article as: Moroti *et al.*: Short-term evaluation of immediately-treated patients with acute HIV infection, recently diagnosed in the National Institute for Infectious Diseases "Prof. Dr. Matei Balș", Bucharest, Romania. *BMC Infectious Diseases* 2014 **14**(Suppl 7):O1.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

